New radiation therapy technique aims to preserve sexual function

June 13, 2018, UT Southwestern Medical Center
Kevin Stanfield is pleased to be participating in the POTEN-C trial, aimed at preserving sexual function in men getting treatment for prostate cancer. Credit: UT Southwestern

Will treatment make me impotent?" It's a question on the minds of many men as they are making decisions about prostate cancer treatment. A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles and arteries involved in sexual function to preserve potency in patients getting radiation therapy for prostate cancer.

"Nowadays, mortality after treatment for localized is as low as 1 percent at 10 years," said Dr. Neil Desai, Assistant Professor of Radiation Oncology, a Dedman Family Scholar in Clinical Care, and Principal Investigator of the POTEN-C trial. "By contrast, as many as half of all patients being treated for cancer will experience some decline in sexual function. It is appropriate, therefore, that our focus has shifted to this aspect of quality of life."

The new technique being tested involves reducing the dose of radiation on one side of the prostate, where imaging shows no cancer, in order to spare nerves and blood vessels on that side. To achieve this goal, patients in the study will be treated with a highly precise form of radiation called stereotactic ablative radiotherapy (SAbR), and a spacer gel (SpaceOAR) will be placed between the rectum and prostate, which may help reduce the radiation dose to nerve bundles involved in . Half the patients in the study will be randomly assigned to the new radiation technique with reduced dosage on one side and half will receive standard SAbR.

Kevin Stanfield of Mount Vernon, Texas, said he became a detective, scoping out all the options—watch-and-wait surveillance, surgery, radiation—when he learned he had prostate cancer, which had taken his grandfather's life. Radiation and participation in the POTEN-C trial were the options Mr. Stanfield chose.

"The potency was a big deal," said Mr. Stanfield. "It's not that I'm some sort of Romeo or anything, but my wife is a few years younger than me. We enjoy our time together."

Mr. Stanfield will be one of 120 patients enrolled in the study, which will include patients at up to nine major medical center sites. All patients in the study will be followed for two years. UT Southwestern will lead the clinical trial. Hear Mr. Stanfield discuss his journey.

The POTEN-C trial builds on prior work done at UT Southwestern Medical Center, which is recognizing its 75th year in 2018.

Dr. Robert Timmerman, Professor of Radiation Oncology and Neurological Surgery, has been at the forefront of national efforts to advance stereotactic ablative radiotherapy, or high-intensity, high-precision in prostate cancer. SAbR means fewer radiation treatments for patients as well as less damage to healthy tissue, and it has become standard treatment in many situations. Dr. Timmerman holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research.

UT Southwestern also was part of clinical proving the value of the biodegradable spacer gel SpaceOAR that is used to protect the rectum from damage during treatment for prostate .

The POTEN-C trial incorporates both prior projects, culminating in what Dr. Desai hopes will be a way to reduce the burden of therapy on men and their partners. "We're using advances in MRI imaging to locate the disease, the SAbR technique's precision, and now the SpaceOAR gel to plan a new approach to reducing sexual dysfunction. We are excited to be able to combine the results from the last 10 years of research to improve the outlook for our who require ."

Mr. Stanfield said he realizes as a participant in a blinded randomized study, there's no guarantee he will get the nerve bundle-sparing technique, but that doesn't bother him. "I might get the new treatment or I might not; however, if I don't I will still get the best that's available now. I'm really excited about being a part of this," he said.

"Basically, we're trying to give men more choices, trying to preserve their potency upfront. If this ends up being a positive trial, it's a pretty big deal for our field," Dr. Desai said.

Explore further: Shorter courses of prostate cancer radiotherapy are safe and effective

Related Stories

Shorter courses of prostate cancer radiotherapy are safe and effective

April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients, according to research presented at the ESTRO 37 conference today.

Sexual function concerns not always reflected in prostate cancer treatment choices

October 25, 2017
Preserving sexual function was important to many men facing treatment for prostate cancer, according to a recent study by University of North Carolina Lineberger Comprehensive Cancer Center researchers. However, this preference ...

Prostate cancer trial shows treating with precision radiotherapy cuts course of treatment by 50 percent

March 16, 2017
An Ontario-led international clinical trial with 1,206 men with localized prostate cancer shows that compressing radiation treatments into four weeks from eight delivers similar outcomes.

Research shows 98 percent cure rate for prostate cancer using SBRT

April 18, 2016
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold ...

Active surveillance preserves quality of life for prostate cancer patients

March 21, 2017
Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released ...

Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer

June 2, 2011
In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk ...

Recommended for you

First major study comparing robotic to open surgery published in The Lancet

June 21, 2018
The first comprehensive study comparing the outcomes of robotic surgery to those of traditional open surgery in any organ has found that the surgeries are equally effective in treating bladder cancer. The seven-year study, ...

Antibodies may predict transplant rejection risk

June 19, 2018
The presence of certain antibodies in patients may suggest a higher risk of transplant rejection across multiple organ types, including the kidney, liver, heart and lungs, according to a new study published in PLOS Medicine.

First human test of robotic eye surgery a success

June 18, 2018
Researchers from the University of Oxford have completed the first successful trial of robot-assisted retinal surgery.

Surgical blood transfusions tied to clot risk

June 13, 2018
(HealthDay)—Blood transfusions around the time of surgery may raise your risk for dangerous blood clots, researchers say.

Tonsil and adenoid removal associated with respiratory, allergic and infectious disease

June 7, 2018
Tonsil and adenoid removal associated with long-term risks of respiratory, allergic and infectious diseases Removing tonsils and adenoids in childhood increases the long-term risk of respiratory, allergic and infectious diseases, ...

Clues found to early lung transplant failure

May 21, 2018
Among organ transplant patients, those receiving new lungs face a higher rate of organ failure and death compared with people undergoing heart, kidney and liver transplants. One of the culprits is inflammation that damages ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.